- AU$92.05bn
- AU$107.79bn
- $15.80bn
Brief: CSL To Launch Clinical Trials To Evaluate Enhanced Plasma Manufacturing
Brief: Csl Reports Positive Top-Line Phase 3B Results Supporting Planned Expanded Pediatric Filing For Andembry® (Garadacimab-Gxii) In Children With Hereditary Angioedema (Hae)
Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine (updated)
EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour
Australian healthcare stocks at two-month high, CSL rises over 3%
Brief: CSL To Cease New Patient Initiation For Tavneos In EU And Eea Markets
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX
Moderna's mRNA flu vaccine backed by FDA advisers (updated)
Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny
Factbox: Global drugmakers invest billions to boost US presence
Brief: UK'S MHRA Grants Marketing Authorisation For AUJEMFLU To Protect Adults Over 50 Against Flu
Morningstar maintains fair value for CSL despite underperformance
Australia's CSL falls on Jefferies downgrade to "hold"
Brief: Australia's Therapeutic Goods Administration Says Seqirus To Discontinue Benpen Injection Products
CSL's Seqirus to discontinue bacterial infection drug amid generic competition (updated)